New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
07:24 EDTPFE, NVS, RHHBYItaly pursues drug firms for anti-trust compensation, Reuters says
Italy said it was seeking over EUR1B in compensation from multinational drug firms after a ruling by the country's antitrust authority that their policies had been damaging to Italy's national health service, according to Reuters, citing a company statement from the country's health ministry. The health ministry requested EUR1.2B total from Novartis (NVS) and Roche (RHHBY) and EUR14M from Pfizer (PFE). Reference Link
News For RHHBY;NVS;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
February 1, 2016
08:09 EDTPFEOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.
06:58 EDTPFEPortola Pharma licensed right to andexanet alfa to Bristol-Myers and Pfizer
Subscribe for More Information
06:57 EDTPFEBristol-Myers and Pfizer sign collaboration with Portola Pharmaceuticals
Subscribe for More Information
January 31, 2016
16:13 EDTRHHBYGenentech receives orphan designation for Avastin in mesothelioma
Subscribe for More Information
January 29, 2016
14:44 EDTPFEPfizer volatility elevated into Q4 and outlook
Subscribe for More Information
07:53 EDTNVSNovartis management to meet with JPMorgan
Subscribe for More Information
07:37 EDTNVSRadius Health should be bought aggressively at current prices, says Canaccord
Canaccord said they would be aggressive buyers of Radius Health (RDUS) especially at current share prices. The firm cited its partnership with Novartis (NVS), its drug pipeline, and expectations for an FDA filing of abaloparatide in the first quarter of 2016. Canaccord reiterated its Buy rating and $85 price target on Radius Health shares.
05:39 EDTPFEPfizer: LIS awards infliximab biosimilar tender to Inflectra, Reuters reports
Pfizer says that the Norwegian Drug Procurement Cooperation has awarded its product Inflectra an infliximab biosimilar tender, Reuters reports. Reference Link
January 28, 2016
12:09 EDTNVSRadius Health to hold a conference call
Subscribe for More Information
09:38 EDTNVSNovartis downgraded to Neutral from Outperform at Exane BNP Paribas
Subscribe for More Information
05:48 EDTRHHBYRoche expects 2016 sales to grow low- to mid-single digit
Subscribe for More Information
05:48 EDTRHHBYRoche board recommends dividend increase to CHF 8.10 per share
Subscribe for More Information
05:47 EDTRHHBYRoche reports FY15 core EPS CHF 13.49 vs. CHF 14.29 last year
05:46 EDTRHHBYRoche reports FY15 Group sales CHF 44.15B vs. CHF 47.46B last year
Subscribe for More Information
05:37 EDTRHHBYAbbVie announces venetoclax granted Breakthrough Therapy Designation by FDA
Subscribe for More Information
January 27, 2016
16:33 EDTNVSRadius Health announces clinical collaboration with Novartis
Subscribe for More Information
12:19 EDTRHHBY, NVSPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:02 EDTRHHBYEli Lilly and Roche to collaborate on Alzheimer's diagnostic tool
Subscribe for More Information
05:22 EDTNVSNovartis sees FY16 revenue, core operating income in line with FY15
Group net sales and core operating income in 2016 are expected to be broadly in line with the prior year, after absorbing the impact of generic competition. Generic competition impact on sales is expected to be as much as $3.2B compared to $2.2B in 2015.
05:20 EDTNVSNovartis reports Q4 core EPS $1.14, consensus $1.18
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use